Noxopharm Ltd has released a press release.
HERACLES clinical trial Update 5
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- First dose in HERACLES clinical trial Part Two
- Second part of HERACLES clinical trial begins
- September 2025 Quarterly Activities Report and Appendix 4C
- First US patent for Sofra technology platform
- Extension of Convertible Notes and Funding
Later from Noxopharm
- HERACLES clinical trial successfully completed
- December 2025 Quarterly Activities Report and Appendix 4C
- Sofra breakthrough science publish in major medical journal
- At-the-Market (ATM) agreement with Acuity Capital
- R&D rebate strengthens cash position
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm